Moxonidin Stada (Moxonidine)

Moxonidine, the active ingredient in Moxonidin Stada, is an imidazoline receptor agonist presented as a tablet for oral use. It treats essential hypertension in adults by lowering blood pressure. GNH USA supplies Moxonidin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine acts on the sympathetic nervous system to control blood pressure in hypertensive patients. - Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. - Mild to moderate hypertension: helps achieve target blood pressure when lifestyle measures are insufficient. - Hypertension as part of combination therapy: can be added to other antihypertensives to improve overall control.

Moxonidine may cause a range of adverse reactions.

Common Side Effects: - Dry mouth: sensation of oral dryness without obvious cause. - Fatigue: feeling unusually tired or lacking energy. - Dizziness: light‑headedness, especially when standing quickly. - Headache: mild to moderate pain in the head region.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Bradycardia: unusually slow heart rate that can lead to dizziness or fatigue. - Allergic reaction: rash, itching, swelling, or difficulty breathing indicating hypersensitivity.

Before initiating therapy, clinicians should consider several safety aspects. - Monitor blood pressure: check regularly to ensure adequate control and avoid excessive lowering. - Adjust dose in renal impairment: reduce dosage if kidney function is compromised. - Caution in cardiovascular disease: evaluate risk of bradycardia or heart block. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Use with caution in elderly patients: start at lower dose and monitor closely. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Moxonidine may interact with other medicines, altering its effect or safety profile.

Major Interactions (Avoid): - Clonidine: combined central antihypertensive effect can cause profound hypotension. - Other central antihypertensives (e.g., rilmenidine): additive blood‑pressure lowering may be unsafe. - Tricyclic antidepressants: may enhance sympathetic inhibition and increase hypotensive risk.

Moderate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response. - Alcohol: may potentiate dizziness and hypotension. - Diuretics: concurrent use may require closer blood‑pressure monitoring.